Data / Drug companies / Minocycline hydrochloride
Minocycline hydrochloride: 29 companies and 127 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Minocycline hydrochloride is listed in the FDA National Drug Code Directory by 29 companies, with 127 products in commercial distribution. 125 of the products (98.4%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; tablet, film coated, extended release; tablet, extended release, and the newest product started marketing on February 3, 2026.
The request: Get every company that lists minocycline hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 29
- Products
- 127
- Generic (ANDA) products
- 125 (98.4%)
- Application numbers
- 17
- Routes
- Oral, Intravenous
- Brand names
- Minocin, Arestin
- openFDA record search
- api.fda.gov
Companies that list minocycline hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Aurobindo Pharma Limited | 11 | tablet, film coated, extended release; capsule | Generic drugs (ANDA) | August 21, 2019 |
| Bryant Ranch Prepack | 11 | tablet, film coated, extended release; capsule | Generic drugs (ANDA) | December 23, 2019 |
| Zydus Lifesciences Limited | 11 | tablet, extended release; capsule | Generic drugs (ANDA) | June 12, 2025 |
| Zydus Pharmaceuticals USA Inc. | 11 | tablet, extended release; capsule | Generic drugs (ANDA) | June 12, 2025 |
| Bryant Ranch Prepack | 10 | capsule; tablet, film coated, extended release | Generic drugs (ANDA) | September 30, 2016 |
| Bryant Ranch Prepack | 9 | tablet, film coated, extended release; capsule | Generic drugs (ANDA) | December 23, 2019 |
| Ascend Laboratories, LLC | 8 | tablet, film coated, extended release | Generic drugs (ANDA) | December 23, 2019 |
| PD-Rx Pharmaceuticals, Inc. | 8 | tablet, film coated, extended release | Generic drugs (ANDA) | December 23, 2019 |
| Torrent Pharmaceuticals Limited | 6 | tablet; capsule | Generic drugs (ANDA) | April 2, 2015 |
| A-S Medication Solutions | 4 | capsule | Generic drugs (ANDA) | April 2, 2015 |
| Lupin Pharmaceuticals, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | February 22, 2019 |
| Aurobindo Pharma Limited | 3 | tablet, film coated | Generic drugs (ANDA) | May 1, 2020 |
| Chartwell RX, LLC | 3 | tablet | Generic drugs (ANDA) | December 26, 2007 |
| NuCare Pharmaceuticals,Inc. | 3 | capsule | Generic drugs (ANDA) | April 2, 2015 |
| Proficient Rx LP | 3 | capsule | Generic drugs (ANDA) | April 2, 2015 |
| Proficient Rx LP | 3 | capsule | Generic drugs (ANDA) | May 13, 2013 |
| Strides Pharma Science Limited | 3 | tablet | Generic drugs (ANDA) | April 11, 2022 |
| Advanced Rx of Tennessee, LLC | 2 | capsule | Generic drugs (ANDA) | May 23, 2024 |
| Northwind Health Company, LLC | 2 | capsule | Generic drugs (ANDA) | January 24, 2023 |
| PD-Rx Pharmaceuticals, Inc. | 2 | capsule | Generic drugs (ANDA) | May 1, 1993 |
| Remedyrepack Inc. | 2 | capsule | Generic drugs (ANDA) | February 3, 2026 |
| Actavis Pharma, Inc. | 1 | capsule | Generic drugs (ANDA) | May 1, 1993 |
| American Health Packaging | 1 | capsule | Generic drugs (ANDA) | February 1, 2018 |
| Major Pharmaceuticals | 1 | capsule | Generic drugs (ANDA) | April 2, 2015 |
| Melinta Therapeutics, LLC | 1 | injection | New drug applications (NDA) | April 19, 2013 |
| Northwind Health Company, LLC | 1 | capsule | Generic drugs (ANDA) | October 4, 2023 |
| OraPharma, Inc. | 1 | powder | New drug applications (NDA) | March 21, 2011 |
| PD-Rx Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | April 2, 2015 |
| Preferred Pharmaceuticals Inc. | 1 | capsule | Generic drugs (ANDA) | November 6, 2017 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 48 | 37.8% |
| Tablet, film coated, extended release | 44 | 34.6% |
| Tablet, extended release | 20 | 15.7% |
| Tablet | 10 | 7.9% |
| Tablet, film coated | 3 | 2.4% |
| Injection | 1 | 0.8% |
| Powder | 1 | 0.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 125 | 98.4% |
| New drug applications (NDA) | 2 | 1.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Tetracycline-class Drug | 127 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.